Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cartalax vs Vesugen
An educational, source-based comparison of Cartalax and Vesugen — how each peptide works, what it's researched for, and what to know before going deeper.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
A synthetic tripeptide (Lys-Glu-Asp) in the Khavinson bioregulator family. Research indicates modulation of endothelial cell function and vascular wall gene expression, supporting vascular tone and microcirculation.
- Vascular endothelial function
- Microcirculation in aging
- Peripheral vascular disorders
- • Russian-origin research; independent replication limited.
- • Not FDA-approved.
Cartalax vs Vesugen — Key differences
- Class: Cartalax is classified as Musculoskeletal · Bioregulator, while Vesugen is Vascular · Bioregulator.
- Primary research focus: Cartalax — osteoarthritis and cartilage repair; Vesugen — vascular endothelial function.
- Tag: Joint · Bioregulator vs Vascular · Bioregulator.